Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kunxian Capsule versus methotrexate for moderate to severe plaque psoriasis
ChiCTR1900025165Phase 4Not yet recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Kunxian Capsule and methotrexate in plaque psoriasis (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoint: PASI 75 response rate. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
Kunxian Capsulemethotrexate
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR1900025165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025165.